If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Yes Soup. I guess we'll have to see just how much groundwork DG actually did when he was a paid consultant. He should have been busy squaring them off against each off against each other for a nice bid war...I wish.
As for ria, Swazer is probably the best bet for some training in the old tea leaves, no?
"Anyone who has to forgo milestones is in a desperate state"
Were you grinning when you wrote that?
£70m upfront (just under 10p a share) or.......wait for it ..... .milestones (probably capped at £2m a year :0)
I'm holding out for ria.
Soup, the Oxilio is worthless to Nuformix.
Weren't we all under the impression before the deal that they were only licensing it for oncology (i.e. treatment for cancer as opposed to the side-effects of treatment)? Then it transpired that we didn't retain any rights to development CINV ourselves.
Even if Oxilio did develop CINV, what is the most we could expect from them?
"With that in mind the key Q&A questions are around funding streams post October."
I would think investors should be more focussed on questioning BD activity to date.
People will remember that DG was engaged as a Business Development Consultant for a number of months prior to becoming executive director. A Proactive video was also released back in November touting Nuformix as 'showcasing' to a conference packed with potential partners:
https://www.proactiveinvestors.co.uk/companies/news/993498/nuformix-showcases-proprietary-tranilast-programme-to-potential-licensing-partners-993498.html
Surely some groundwork was done in that time (first contacts made etc...)
DG has said they have everything they need to push ahead with partnering. Investors should be more interested in learning how that is developing. That is the funding we should really be interested in now.
Seems little point in chasing further discounted, dilutive offerings to unamed 'institutionals' unless we can attract some interest from prospective partners.
It seems that there is a potential market for muscling in on SOC rather than just going it alone after all. Even big pharma are doing it.
New drug combo promises to hold back Ovarian cancer for FIVE YEARS https://mol.im/a/12156223
"Current NHS treatment for those without the BRCA mutation typically involves surgery, chemotherapy and an immunotherapy drug called bevacizumab. But in this new study, which involved 1,100 patients, a third of participants received chemotherapy and bevacizumab followed by two other drugs: durvalumab and olaparib."
It's a shame NXP004 appears to have slipped onto the back burner. Still, if they can partner NXP002 with big pharma (as opposed to minnow associates via worthless licensing deals) then maybe focus will return to that somewhere down the road.
I did say I was being flippant Whimax but it's always a pleasure to see you getting your knickers in a twist.
These videos are mainly put out on channels which reach no-one but an audience of traders. All that is likely to get us is a series of pump n dumps instead of touching base with partners who can make a real difference to the valuation....but maybe that's enough for you. At least you might get your 2% that way.
If the board are serious then there is much more work to be done. Satisfying the whims of short term traders will achieve nothing, I'm afraid.
I look forward to hearing more about the business development efforts that were undertaken in preparation for this good news that we recently received.